JLE

European Journal of Dermatology

MENU

Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis Volume 29, issue 4, July-August 2019

Figures


  • Figure 1
Authors
1 Department of Dermatology,
2 Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Biologics may induce organ-specific and systemic autoimmune diseases as adverse events [1, 2]. Isolated cases of paradoxical ulcerative colitis (PUC) due to anti-tumour necrosis factor-alpha (TNFα) inhibitors, such as adalimumab, have been described [2]. We herein report PUC in a patient with psoriasis during treatment with secukinumab, an interleukin-17A (IL-17A) inhibitor.In October 2014, a 41-year-old woman was referred to us with a 27-year history of gradually progressive, generalized, asymptomatic [...]